XML 215 R28.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Operating Segments | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2024 | Dec. 31, 2023
Operating Segments [Abstract] |  |
OPERATING SEGMENTS | NOTE 11:- OPERATING SEGMENTS The Company applies the principles of IFRS 8, “Operating Segments” (“IFRS 8”), regarding operating segments. The segment reporting is based on internal management reports of the Company’s management, which are regularly reviewed by the Chief Operating Decision Maker (“CODM”) to make decisions about resources to be allocated and assess performance. According to the principles of IFRS 8, the Company’s management determined that it has two reportable segments – (1) development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the Company’s operation); and (2) online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. The review of the CODM is carried out according to the results of the segment’s activity. His review does not include certain expenses that are not related specifically to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating results in financial statements. The Group’s CODM is the CEO of the Company.
|  | Six months ended June 30, 2024 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 840 |  |  | $ | 840 |
Total |  |  | - |  |  |  | 840 |  |  |  | 840 |
Segment loss (gain) |  |  | 3,040 |  |  |  | 487 |  |  |  | 3,527 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 208 |
Loss on impairment of intangible asset |  |  |  |  |  |  |  |  |  |  | - |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (51 | )
Tax expense (income) |  |  |  |  |  |  |  |  |  |  | (5 | )
Loss |  |  |  |  |  |  |  |  |  |  | 3,679 |
|  | Six months ended June 30, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 1,972 |  |  | $ | 1,972 |
Total |  |  | - |  |  |  | 1,972 |  |  |  | 1,972 |
Segment loss (gain) |  |  | 2,772 |  |  |  | 195 |  |  |  | 2,967 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 99 |
Loss on impairment of intangible asset |  |  |  |  |  |  |  |  |  |  | - |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (147 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 13 |
Loss |  |  |  |  |  |  |  |  |  |  | 2,932 |
|  | Year ended December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 2,879 |  |  | $ | 2,879 |
Total |  |  | - |  |  |  | 2,879 |  |  |  | 2,879 |
Segment loss (gain) |  |  | 5,359 |  |  |  | 414 |  |  |  | 5,773 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 210 |
Loss on impairment of intangible asset |  |  |  |  |  |  |  |  |  |  | 1,042 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (1,164 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 22 |
Loss |  |  |  |  |  |  |  |  |  |  | 5,883 |
|  | As of June 30, 2024 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 6,834 |  |  | $ | 3,648 |  |  | $ | 10,482 |
Segment Liabilities |  | $ | 1,742 |  |  | $ | 84 |  |  | $ | 1,826 |
|  | As of June 30, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 4,290 |  |  | $ | 5,602 |  |  | $ | 9,892 |
Segment Liabilities |  | $ | 2,741 |  |  | $ | 373 |  |  | $ | 3,114 |
|  | As of December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 7,069 |  |  | $ | 4,113 |  |  | $ | 11,182 |
Segment Liabilities |  | $ | 1,441 |  |  | $ | 154 |  |  | $ | 1,595 |
NOTE 23:- | OPERATING SEGMENTS
The Company applies the principles of IFRS 8, “Operating Segments” (“IFRS 8”), regarding operating segments. The segment reporting is based on internal management reports of the Company’s management, which are regularly reviewed by the Chief Operating Decision Maker (“CODM”) to make decisions about resources to be allocated and assess performance. According to the principles of IFRS 8, the Company’s management determined that it has two reportable segments – (1) development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the Company’s operation); and (2) online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. The review of the CODM is carried out according to the results of the segment’s activity. His review does not include certain expenses that are not related specifically to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating results in financial statements. The Group’s CODM is the CEO of the Company.
|  | Year ended December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 2,879 |  |  | $ | 2,879 |
Total |  |  | - |  |  |  | 2,879 |  |  |  | 2,879 |
Segment loss (gain) |  |  | 5,359 |  |  |  | 414 |  |  |  | 5,773 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 210 |
Loss on impairment of intangible asset |  |  |  |  |  |  |  |  |  |  | 1,042 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (1,164 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 22 |
Loss |  |  |  |  |  |  |  |  |  |  | 5,883 |
|  | Year ended December 31, 2022 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | 1,347 |  |  | $ | 1,347 |
Total |  |  | - |  |  |  | 1,347 |  |  |  | 1,347 |
Segment loss |  |  | 8,405 |  |  |  | (118 | ) |  |  | 8,287 |
Company’s share of losses of company accounted for at equity, net |  |  |  |  |  |  |  |  |  |  | 109 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | (5,818 | )
Tax expense |  |  |  |  |  |  |  |  |  |  | 14 |
Loss |  |  |  |  |  |  |  |  |  |  | 2,592 |
|  | Year ended December 31, 2021 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Revenues |  |  |  |  |  |  |  |  |
External |  | $ | - |  |  | $ | - |  |  | $ | - |
Total |  |  | - |  |  |  | - |  |  |  | - |
Segment loss |  |  | 5,768 |  |  |  | - |  |  |  | 5,768 |
Finance expense (income), net |  |  |  |  |  |  |  |  |  |  | 21 |
Loss |  |  |  |  |  |  |  |  |  |  | 5,789 |
|  | As of December 31, 2023 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 7,069 |  |  | $ | 4,113 |  |  | $ | 11,182 |
Segment Liabilities |  | $ | 1,441 |  |  | $ | 154 |  |  | $ | 1,595 |
|  | As of December 31, 2022 |
|  | Drug Development |  |  | Online Sales |  |  | Total |
Segment Assets |  | $ | 9,664 |  |  | $ | 941 |  |  | $ | 10,605 |
Segment Liabilities |  | $ | 4,021 |  |  | $ | 135 |  |  | $ | 4,156 |

X
- Definition The entire disclosure for operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration